ÂÜÀòÂÒÂ×

Suki Kandola has extensive work experience in various roles within the healthcare industry. Suki is currently the Global Head of Commercial Strategy, Value & Access at Envision Pharma Group since January 2022. Prior to this role, they served as the Global Head, Health Economics & Market Access from January 2018 to December 2021, and as the Vice President, Health Economics & Market Access from January 2015 to December 2017 at the same company. Before joining Envision Pharma Group, Suki held the position of Senior Director, HEOR & Market Access at Indegene, HERON (Parexel), Separation Science from January 2012 to December 2014. Suki also worked as the Director, Europe and ROW at Tosoh Corporation from January 2010 to December 2011, as well as the Senior Manager, UK Key Accounts at Thermo Fisher Scientific from January 2006 to January 2010. Suki began their career as a Principal Scientist at GlaxoSmithKline in 2005.

Suki Kandola's education history is as follows:

In an unspecified year, Suki attended the Instituto Canossiano Venice where they received an EU Scholarship and studied Green Chemistry. After that, they pursued a PhD in Research Chemistry at the University of Leicester & GlaxoSmithKline UK from 2000 to 2003. From 2004 to 2005, Suki attended the University of Colorado Denver for the WorldSmart Leadership Program. Later, from 2008 to 2011, they pursued an MBA in Global Management at Grenoble Ecole de Management, where they graduated with distinction. In 2016, Suki briefly attended The London School of Economics and Political Science (LSE) for a Health Policy course.